Clinical Trial: Efficacy and safety of the combination of gilitinib, sonrotoclax and chidamide in the treatment of newly diagnosed AML with FLT3 mutations: A prospective, single-arm, multicenter, exploratory clinical trial (China)

China, Aug. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety of the combination of gilitinib, sonrotoclax and chidamide in the treatment of newly diagnosed AML with FLT3 mutations: A prospective, single-arm, multicenter, exploratory clinical trial'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129978

Registration Time: 2026/08/12

Type: Interventional study

Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=330761

Published by HT Digital Content Services with permission from Health Daily Digest....